One thing we have learned during the pandemic is that medical innovation cannot rest on its laurels. We should expect that the Centers for Disease Control and Prevention that provides swift and straightforward recommendations.
We should not wait for the subsequent pandemic or variant mutation as a society. Instead, we must ensure that we are always one step ahead of the next public health crisis.
Multiple innovators are on the cusp of developing new treatments and vaccines to defeat the coming variants of COVID-19 or the old public health nemesis, the flu. For example, there are promising antibody therapies under review at the FDA that treat and prevent COVID infections.
While innovation against flu continues, there are already approved enhanced vaccines for influenza. The latter vaccines are referred to as Enhanced Influenza Vaccines (EIVs). Multiple such vaccines are currently available in the marketplace, which provides healthcare professionals and patients numerous access opportunities.
Most important, all EIVs have promoted a better vaccine response for older adults.
Earlier this year, the Advisory Committee on Immunization Practices influenza working group presented data that one does not promote A simple recommendation from ACIP that older patients should provide more certainty to healthcare professionals and their patients. Such guidance will ensure the supply of the EIVs is robust, as several different manufacturers will be involved in supplying these vaccines. In addition, providing widespread flu vaccination with improved effectiveness could be especially important for the 2022-23 season. Not only will there be a harbinger of the winter in the Southern Hemisphere, which has been surging in the last several weeks.
Of healthcare professionals, we focus on helping our patients achieve a healthy life – sometimes with medications that treat disease and progressively more in administering vaccines and other preventive therapies. The recent US biopharmaceutical innovation model. After all, it is because of the current system that we have effective vaccines, antibody therapies and oral antivirals available and in development.
We should always strive for a better therapy while championing the competitive market forces that help balance our patients’ economic and outcomes needs.
Opportunities to provide preventive treatments such as EIVs while improving competition through multiple biopharmaceutical companies manufacturing the vaccines are a win-win for everyone involved and in our pursuit of better patient care and lower healthcare costs.